SLC5A2 and metabolic dysfunction-associated steatotic liver disease: It is unclear whether this effect on NAFLD is independent of weight-loss, a caveat that extends to SGLT2 inhibitors, which also demonstrate some benefit for NAFLD treatment in adults (58).